J.P. Morgan Securities LLC Xeris Pharmaceuticals, Inc Amend 8.3 (9478J)
26 Agosto 2021 - 12:19PM
UK Regulatory
TIDM0A8E
RNS Number : 9478J
J.P. Morgan Securities LLC
26 August 2021
Ap19
AMMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing J.P. Morgan Securities
(Note 1) LLC
Company dealt in Xeris Pharmaceuticals,
Inc.
======================
Class of relevant security $0.001 common stock
to which the dealings
being disclosed relate
(Note 2)
======================
Date of dealing 06 August 2021
======================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
======= ==== ==== ========= ==== ====
(1) Relevant securities 4,033,591 6.07 134,463 0.20
------------------- ---------------------
(2) Derivatives (other
than options) 124,443 0.19
------------------- ---------------------
(3) Options and agreements
to purchase/sell
------------------- ---------------------
Total 4,158,034 6.26 134,463 0.20
------------------- ---------------------
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(USD)
(Note 5)
Purchase(New Borrow) 28,800 N/A
Purchases 1,770,701 2.4000 USD
Sales 1,500 2.3100 USD
Sales 1,700 2.3125 USD
Sales 100 2.3150 USD
Sales 52,776 2.3156 USD
Sales 799 2.3187 USD
Sales 700 2.3200 USD
Sales 21,146 2.3204 USD
Sales 378 2.3250 USD
Sales 4,878 2.3300 USD
Sales 22,327 2.3306 USD
Sales 3,814 2.3332 USD
Sales 2,699 2.3339 USD
Sales 2,495 2.3350 USD
Sales 13,813 2.3358 USD
Sales 1,869 2.3400 USD
Sales 38,178 2.3401 USD
Sales 36,716 2.3429 USD
Sales 23,900 2.3442 USD
Sales 22,938 2.3450 USD
Sales 2,964 2.3500 USD
Sales 5,800 2.3502 USD
Sales 23,489 2.3509 USD
Sales 1,257 2.3513 USD
Sales 11,666 2.3541 USD
Sales 3,198 2.3542 USD
Sales 21,336 2.3550 USD
Sales 19,376 2.3572 USD
Sales 30,753 2.3573 USD
Sales 6,845 2.3600 USD
Sales 13,200 2.3609 USD
Sales 7,502 2.3622 USD
Sales 14,350 2.3627 USD
Sales 5,926 2.3634 USD
Sales 3,641 2.3650 USD
Sales 5,822 2.3690 USD
Sales 3,952 2.3700 USD
Sales 6,377 2.3748 USD
Sales 11,000 2.3750 USD
Sales 4,357 2.3763 USD
Sales 2,151 2.3800 USD
Sales 5,000 2.3850 USD
Sales 3,900 2.3867 USD
Sales 1,500 2.3903 USD
Sales 57,400 2.3950 USD
Sales 5,145 2.4000 USD
Sales 12,384 2.4035 USD
Sales 193 2.4050 USD
Sales 1,099 2.4100 USD
Sales 29,593 2.4135 USD
Sales 900 2.4144 USD
Sales 18,018 2.4183 USD
Sales 693 2.4200 USD
Sales 10,768 2.4207 USD
Sales 19,067 2.4263 USD
Sales 5,307 2.4312 USD
Sales 1,460 2.4438 USD
Sales 2,780 2.4500 USD
Sales 1,100 2.4550 USD
Sales 4,119 2.5200 USD
Sales 799 2.5250 USD
Sales 3,446 2.5300 USD
====================================== ====================
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per
e.g. CFD (Note 6) securities unit
(Note 7) (USD) (Note
5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If none, this
should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 26 August 2021
Contact name Alwyn Basch
===============
Telephone number 0207 742 7407
===============
If a connected EFM, name N/A
of offeree/offeror with
which connected
===============
If a connected EFM, state N/A
nature of connection (Note
10)
===============
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISESEWFWMEFSEFA
(END) Dow Jones Newswires
August 26, 2021 13:19 ET (17:19 GMT)
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024
